Home > Resources > Whitepapers > When uncertainty is the only certainty, should biotechs adapt or stay the course?

When uncertainty is the only certainty, should biotechs adapt or stay the course?

Biotechnology executives and investors know the drill: take advantage of robust financing, but prepare for its inevitable decline. As we review in our 31st annual Beyond borders, in 2016, biotechnology companies continued to invest in tomorrow’s treatments even as capital markets in the US and EU dried up, valuations suffered and payers commanded ever more decision-making power. There were geopolitical complexities, too: Brexit; the Trump presidency; ongoing uncertainty about US health care reform.

Spotlight

MacroGenics, Inc.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. MacroGenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines.

OTHER WHITEPAPERS

How advanced purification technologies are speeding the hunt for new protections against disease

whitePaper | November 24, 2022

Smallpox was the first infectious disease for which an effective vaccine was developed. In the late 1700s, British doctor Edward Jenner devised a method to inoculate people with cowpox pus to give them immunity against smallpox, a much more deadly disease.